Search

Search Constraints

You searched for: Author/Creator Weichenthal, Michael

Search Results

31. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. Issue 2 (22nd October 2020)

32. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. Issue 2 (22nd October 2020)

33. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. Issue 2 (22nd October 2020)

34. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. Issue 2 (22nd October 2020)

35. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. Issue 2 (22nd October 2020)

36. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. Issue 2 (22nd October 2020)

37. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. Issue 1 (5th May 2020)

38. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. Issue 6 (10th June 2022)

39. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. Issue 11 (30th November 2022)

40. Kutane Nebenwirkungen der Kombinationstherapie mit Sorafenib und pegyliertem Interferon alfa‐2b bei metastasiertem Melanom (ADO SoraPeg‐Studie). (19th August 2013)